VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 21, 2009) - PMI Labs will be exhibiting OralAdvance™, an informative new test for assessing the malignant potential of oral lesions, on May 21 - 24, 2009 at the Jasper Dental Congress (Jasper, Alberta) at booth 303 and on May 25 - 26, 2009 at the Journees Dentaires Internationals du Quebec (Montreal, Quebec) at booth 202.
With recent advances in visualization techniques for the oral cavity, dentists are encountering more suspicious lesions. OralAdvance™, with its soft cyto-brush sample collection kit, provides dentists with an informative new option for assessing these lesions when biopsy is not warranted or possible. It provides an objective measure of gross DNA abnormality that can give additional information about the pre-malignant or malignant nature of a lesion.
About PMI Labs
Perceptronix Medical Inc. Laboratories (Vancouver, Canada) provide anatomic pathology and cancer diagnostics services to medical and dental practices in support of earlier diagnoses for better patient outcomes. PMI Labs offers anatomic pathology services with specialized expertise in oncologic pathology, cytopathology, oral pathology, and pathology consultation.
The company uniquely specializes in early cancer detection using quantitative cytology, including tests for oral cancer (OralAdvance™) and lung cancer (LungSign™). Quantitative cytology provides physicians with a distinctive cytopathology assessment based on an objective, computer-based measurement of large-scale DNA abnormality that can indicate precancerous or cancerous changes.